Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIS410 single-dose intravenous challenge study in healthy adults inoculated with influenza A (H1N1)
2015-000574-35Phase 2Completed
- Sponsor
- Visterra
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Influenza A infection comparing VIS410 with Placebo (2 arms). Primary endpoints: Post-infusion adverse events within 1 hour, Safety profile of VIS410 and 1 more. Started Mar 2015; status: completed.
02
Drugs
VIS410
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on 2015-000574-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000574-35.